Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302
Filed with ASX · · 5 pages · English
Earlier from Opthea
- Opthea European Patent Application to be Granted
- Opthea Provides Timing Update on OPT-302 Clinical Trials
- Opthea Completes Final Patient Visit in Phase 2b wAMD Trial
- S&P DJI Announces March 2019 Quarterly Rebalance
- Opthea Ph2b Trial Advances With 2nd Positive Safety Review
Later from Opthea
- Opthea Ph2b of OPT-302 in wAMD to be Presented at EURETINA
- Opthea Presentation for EURETINA Congress
- Opthea Receives A$14.6m R&D Tax Incentive
- Opthea Presentation for Ophthalmology Innovation Summit
- Opthea Equity Raising Presentation
Follow Opthea into a list and get an email when it puts out news.
Follow Opthea